Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

Delayed Quote. Delayed  - 06/27 02:25:47 pm
37 GBp   +0.68%
06/09 DIRECTOR DEALIN : Vernalis CEO And CFO Buy Shares
05/19 VERNALIS : Moxatag Supply Update
05/19 VERNALIS : Says Supplier Of Moxatag Placed In Provisional Liquidatio..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Vernalis plc
Researches and develops pharmaceutical products

Vernalis Plc engages in the research, development, and commercialization of pharmaceutical products under the Tuzistra XR brand.

The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom.

Number of employees : 91 persons.
Sales per Businesses
2015
GBP (in Million)%
Pharmaceuticals13.26100%
Sales per Regions
2015
GBP (in Million)%
Rest of Europe10.2577.4%
Rest of the World2.3217.5%
North America0.6695%
United Kingdom0.0160.1%
Managers
NameAgeSinceTitle
Ian Garland50-Chief Executive Officer & Executive Director
Peter John Fellner, PhD712003Non-Executive Chairman
David MacKney48-Chief Financial Officer & Executive Director
Pascal Borderies, MD-2014Senior Vice President-Medical Affairs
Carol C. Ferguson692003Senior Independent Non-Executive Director
Nigel Sheail502011Independent Non-Executive Director
Ian David Gilham, PhD552015Independent Non-Executive Director
Lisa Amster Schoenberg, MBA492015Non-Executive Director
Kevin Kissane602010Secretary & General Counsel
Mike Wood-2004Research Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 526,054,688 520,396,872 98.9% 0 0.0% 98.9%
Shareholders
NameEquities%
Invesco Asset Management Ltd. 194,441,770 37.0%
Woodford Investment Management LLP 139,557,297 26.5%
GAM London Ltd. 40,715,903 7.74%
Legal & General Investment Management Ltd. 28,672,162 5.45%
Aviva Investors Global Services Ltd. 27,283,011 5.19%
Rothschild Bank AG 11,129,000 2.12%
OppenheimerFunds, Inc. 9,712,000 1.85%
Majedie Asset Management Ltd. 7,004,667 1.33%
EdenTree Investment Management Ltd. 4,750,000 0.90%
River & Mercantile Asset Management LLP 3,094,443 0.59%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
INCYTE CORPORATIO..
CELLTRION, INC.
LONZA GROUP AG
QUINTILES TRANSNA..
ALKERMES PLC
SEATTLE GENETICS,..
QIAGEN NV
ALNYLAM PHARMACEU..
UNITED THERAPEUTI..
ANACOR PHARMACEUT..
BIO-TECHNE CORP
CHARLES RIVER LAB..
ICON PLC
ACADIA PHARMACEUT..
PAREXEL INTERNATI..
INTREXON CORP
BB BIOTECH AG
-
IONIS PHARMACEUTI..
PRA HEALTH SCIENC..
GALAPAGOS
Sector Biotechnology & Medical Research
Vernalis plc : Connections
Biosurfit SA
The Institute of Chartered Accountants of Scotland
Bayer HealthCare
Multiplicom NV
Concepta Diagnostics Ltd.
Chartered Accountants Compensation Scheme Ltd.
Stowheath Ltd.
Company contact information
Vernalis Plc
100 Berkshire Place
Wharfedale Road
Winnersh, Berkshire RG41 5RD

Phone : +44.118.938.0000
Fax : +44.118.938.0001
Web : www.vernalis.com
© 2016 People , Fundamentals and Ownership